A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia

被引:72
|
作者
Chengappa, K. N. Roy [1 ]
Turkin, Scott R. [2 ]
DeSanti, Susan [3 ]
Bowie, Christopher R. [4 ]
Brar, Jaspreet S.
Schlicht, Patricia J.
Murphy, Sherry L. [2 ]
Hetrick, Michelle L. [2 ]
Bilder, Robert [5 ]
Fleet, David [6 ]
机构
[1] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Comprehens Recovery Serv,Sch Med, Pittsburgh, PA 15213 USA
[2] Dubois Reg Med Ctr, Du Bois, PA USA
[3] NYU, Dept Psychiat, Langone Med Ctr New York, New York, NY 10003 USA
[4] Queens Univ, Kingston, ON, Canada
[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[6] Datamagik, London, England
关键词
L-carnosine; Cognition; Schizophrenia; Randomized clinical trial; Set shifting; Perseverative errors; SET-SHIFTING ABILITY; EPISODE SCHIZOPHRENIA; EXECUTIVE FUNCTION; CEREBRAL-ISCHEMIA; MENTALLY-ILL; GLUTAMATE; HISTIDINE; RECEPTORS; PROTECTS; CELLS;
D O I
10.1016/j.schres.2012.10.001
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Targeting glutamatergic dysfunction provides an exciting opportunity to improve cognitive impairment in schizophrenia. One treatment approach has targeted inadequate antioxidant defenses at glutamatergic synapses. Animal and human data suggest NMDA antagonists worsen executive cognitive controls - e.g. increase perseverative responses and impair set-shifting. We conducted a preliminary study to test the hypothesis that L-carnosine, an antioxidant and anti-glycation agent which is co-localized and released with glutamate would improve executive dysfunction, a cognitive domain associated with glutamate. Methods: Seventy-five symptomatically stable adults with chronic schizophrenia were randomly assigned to L-carnosine as adjunctive treatment (2 g/day) or amatched placebo in a double-blindmanner for 3 months. Cognitive domains (executive dysfunction, memory, attention and motor speed) were assessed using a computerized battery at baseline, 4 and 12 weeks, along with psychopathology ratings and safety parameters. Results: The L-carnosine group performed significantly faster on non-reversal condition trials of the set-shifting test compared with placebo but reversal reaction times and errors were not significantly different between treatments. On the strategic target detection test, the L-carnosine group displayed significantly improved strategic efficiency and made fewer perseverative errors compared with placebo. Other cognitive tests showed no significant differences between treatments. Psychopathology scores remained stable. The carnosine group reported more adverse events (30%) compared with the placebo group (14%). Laboratory indices remained within acceptable ranges. Conclusions: These preliminary findings suggest that L-carnosine merits further consideration as adjunctive treatment to improve executive dysfunction in persons with schizophrenia. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:145 / 152
页数:8
相关论文
共 50 条
  • [1] Double-Blind Placebo-Controlled Study of the Effects of Combined L-Carnosine and Cognitive Training on Social Cognition in Schizophrenia
    Reichenberg, Abraham
    NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 24 - 24
  • [2] L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial
    Araminia, Behin
    Shalbafan, Mohammadreza
    Mortezaei, Amirhosein
    Shirazi, Elham
    Ghaffari, Salomeh
    Sahebolzamani, Erfan
    Mortazavi, Seyyed Hosein
    Shariati, Behnam
    Ardebili, Mehrdad Eftekhar
    Aqamolaei, Ali
    Naderi, Sina
    Akhondzadeh, Shahin
    JOURNAL OF AFFECTIVE DISORDERS, 2020, 267 : 131 - 136
  • [3] Cognitive and negative symptoms in schizophrenia with L-Carnosine adjuvant therapy - A randomized double-blind placebo-controlled study
    Tharoor, Hema
    Maran, Sindhu
    Chandan, Antra K.
    Pari, Manikandan
    Rao, Shruti
    Durairaj, Jothilakshmi
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (02):
  • [4] l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
    Hajizadeh-Zaker, Reihaneh
    Ghajar, Alireza
    Mesgarpour, Bita
    Afarideh, Mohsen
    Mohammadi, Mohammad-Reza
    Akhondzadeh, Shahin
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2018, 28 (01) : 74 - 81
  • [5] L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial
    Ghajar, Alireza
    Khoaie-Ardakani, Mohammad-Reza
    Shahmoradi, Zahara
    Alavi, Amir-Reza
    Afarideh, Mohsen
    Shalbafan, Mohammad-Reza
    Ghazizadeh-Hashemi, Maryam
    Akhondzadeh, Shahin
    PSYCHIATRY RESEARCH, 2018, 262 : 94 - 101
  • [6] Lovastatin for the adjunctive treatment of schizophrenia: A preliminary randomized double-blind placebo-controlled trial
    Ghanizadeh, Ahmad
    Rezaee, Zahra
    Dehbozorgi, Sara
    Berk, Michael
    Akhondzadeh, Shahin
    PSYCHIATRY RESEARCH, 2014, 219 (03) : 431 - 435
  • [7] A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia A Preliminary Study
    Niitsu, Tomihisa
    Fujisaki, Mihisa
    Shiina, Akihiro
    Yoshida, Taisuke
    Hasegawa, Tadashi
    Kanahara, Nobuhisa
    Hashimoto, Tasuku
    Shiraishi, Tetsuya
    Fukami, Goro
    Nakazato, Michiko
    Shirayama, Yukihiko
    Hashimoto, Kenji
    Iyo, Masaomi
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (05) : 593 - 601
  • [8] The Impact of Eszopiclone Insomnia Treatment on Cognition in Schizophrenia: A Double-blind, Randomized, Placebo-controlled Trial
    Tek, Cenk
    Palmese, Laura B.
    Krystal, Andrew D.
    DeGeorge, Pamela C.
    Reutenauer, Erin L.
    Guloksuz, Sinan
    BIOLOGICAL PSYCHIATRY, 2014, 75 (09) : 341S - 342S
  • [9] Effects of raloxifene on cognition in postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial
    Huerta-Ramos, Elena
    Iniesta, Raquel
    Ochoa, Susana
    Cobo, Jesus
    Miquel, Eva
    Roca, Mercedes
    Serrano-Blanco, Antoni
    Teba, Fernando
    Usall, Judith
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 (02) : 223 - 231
  • [10] Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders
    Chez, MG
    Buchanan, CP
    Aimonovitch, MC
    Becker, M
    Schaefer, K
    Black, C
    Komen, J
    JOURNAL OF CHILD NEUROLOGY, 2002, 17 (11) : 833 - 837